Company Overview - Hai Ji Ya Medical Holdings Limited is a medical group focused on oncology, listed on the Hong Kong Stock Exchange since June 29, 2020, under stock code 06078.HK [3] - The company operates a network of oncology-focused hospitals and radiotherapy centers across multiple provinces and cities in China, managing or operating 13 hospitals as of June 30, 2023 [3] - The company has established partnerships with 24 third-party hospitals to provide radiotherapy services [3] Financial Performance - For the fiscal year ending December 31, 2024, Hai Ji Ya Medical reported total revenue of 4.446 billion yuan, a year-on-year increase of 9.06% [2] - The net profit attributable to shareholders was 598 million yuan, reflecting a year-on-year decrease of 12.4% [2] - The company's gross margin stood at 29.9%, with a debt-to-asset ratio of 38.93% [2] Stock Performance - As of April 1, the stock price of Hai Ji Ya Medical was 14.78 HKD per share, marking a 9.97% increase with a trading volume of 34.7844 million shares and a turnover of 0.525 billion HKD [1] - Over the past month, the stock has experienced a cumulative decline of 8.94%, and a year-to-date decline of 5.75%, underperforming the Hang Seng Index, which has risen by 15.25% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -18.15 times, with a median of 2.44 times [3] - Hai Ji Ya Medical's P/E ratio is 12.94 times, ranking 25th in the industry [3] - Comparatively, other companies in the sector have significantly lower P/E ratios, such as Giant Medical Holdings at 0.24 times and Jing Jiu Kang Liao at 0.38 times [3] Technological Development - Shanghai Gamma Star Technology Development Co., Ltd., a wholly-owned subsidiary of Hai Ji Ya Medical, has developed a patented stereotactic radiotherapy system for treating tumors [4] - The company employs a vertically integrated radiotherapy service model, enhancing operational efficiency and profitability [4] Shareholder Activity - On March 31, 2025, shareholder Zhu Yiwen increased his holdings by 258,400 shares at an average price of 13.3997 HKD per share, bringing his total holdings to 284.2 million shares, representing 45.7% of the company [5]
海吉亚医疗（06078.HK）4月1日收盘上涨9.97%，成交5.25亿港元